ORIGINAL RESEARCH article
Front. Pharmacol.
Sec. Drugs Outcomes Research and Policies
Volume 16 - 2025 | doi: 10.3389/fphar.2025.1683838
Therapeutic Efficacy of Deslanoside in Oleic Acid-Induced Acute Lung Injury in Rabbits: Implications for Clinical Drug Use and Pharmacological Strategies
Provisionally accepted- Zhuzhou Central Hospital, Zhuzhou, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Background: Acute lung injury (ALI) remains a life-threatening condition with limited effective pharmacological options. Deslanoside, a cardiac glycoside traditionally used in heart failure, has recently attracted attention for its anti-inflammatory and tissue-protective properties. Objective: This study evaluated the therapeutic efficacy of deslanoside in an oleic acid-induced rabbit ALI model and discussed its potential clinical and pharmacological implications. Deslanoside is known to modulate Na⁺/K⁺-ATPase–related signaling and inhibit the NF-κB–mediated inflammatory cascade, which may contribute to its protective effects in ALI. Methods: Thirty healthy male New Zealand white rabbits were randomly assigned to control (saline) or experimental (deslanoside) groups following intravenous oleic acid injection to induce ALI. Modified lung ultrasound (MLUS) scores, arterial blood gas analysis, lung water content, histopathology, and serum levels of TNF-α, IL-1β, and IL-6 were assessed over 12 hours. Results: Compared with controls, deslanoside treatment significantly improved PaO₂, reduced MLUS scores, decreased lung water content, and lowered histopathological injury scores (all P < 0.05). Inflammatory cytokine levels were also markedly reduced (P < 0.05). No acute adverse drug reactions were observed. Conclusion: Deslanoside demonstrated significant protective effects in oleic acid-induced ALI, improving oxygenation, attenuating pulmonary edema, and reducing inflammation. These findings support the potential repositioning of deslanoside as an adjunctive therapy for ALI and provide experimental evidence to inform future clinical drug use strategies and pharmacological policy discussions.
Keywords: Deslanoside, Acute Lung Injury, therapeutic efficacy, Inflammation, Drug Repositioning, pharmacological strategy
Received: 11 Aug 2025; Accepted: 20 Oct 2025.
Copyright: © 2025 Hu, Zheng, Li, Pan, Zhou, Liu, Liao and Liu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yafei Liu, 13873396655@163.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.